Authors: Roisin Conneely, Future Science Group
Results from the TRANSCEND NHL 001 trial have demonstrated promising results for a novel form of CAR T-cell therapy, termed JCAR017, in patients with poor-prognosis relapsed or refractory non-Hodgkin lymphoma. The findings were presented recently at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium (25–27 January, CA, USA).
JCAR017 is a CD19 directed CAR T-cell product, comprising individually formulated CD4+ and CD8+ suspensions, which are administered in a flat dose.
Restricted Content / Members Only